Chemical Compound

Sorafenib

CAS Registry Number 284461-73-0

Back to search Request a Quote

Primary Record

Sorafenib

In stock: 9,523 g
Purity: 99.0 %
CAS: 284461-73-0

Compound Identifiers & Properties

CAS: 284461-73-0
PubChem CID: 216239
SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
Canonical SMILES: CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1

Names & Synonyms

Sorafenib
Nexavar
284461-73-0
Sorafenib tosylate
sorafenibum
Donafenib
Sorafenib [INN]
Chemexper
Sorafenib-d3
Sorafinib
Xarelto
Sorafenib free base
MnTMPyP pentachloride
BAY 43-9006
Sorafenibtosylate
Sorafenib tosilate
1uwh
3gcs
3heg
4asd
Sorafenib (Base)
Sorafenib, 4
Hit compound, 8
Sorafenib (INN)
Nexavar (TN)
Sorafenib (Nexavar)
Sorafenib (Standard)
Kinome_766
SORAFENIB BASE
9ZOQ3TZI87
RefChem:6252
UNII-9ZOQ3TZI87
C21H16ClF3N4O3
SORAFENIB [MI]
MFCD06411450
Sorafenib (USAN/INN)
SORAFENIB [USAN]
Nexavar (TN) (Bayer)
sorafenib tosilate hydrate
CHEMBL1336
SORAFENIB [VANDF]
Donafenib (Sorafenib D3)
DTXSID7041128
Sorafenib [USAN:INN:BAN]
D0W5HK
SORAFENIB [MART.]
AC1L50CF
SCHEMBL8218
SORAFENIB [WHO-DD]
BAY-43-9006
SORAFENIB [EMA EPAR]
CHEBI:50924
HSDB 8173
Sorafenib (Pan-TK inhibitor)
Sorafenib - Bio-X trade mark
284461-73-0 (free base)
MLDQJTXFUGDVEO-UHFFFAOYSA-N
BAY 43-9006; Sorafenib
cid_216239
GTPL5711
orb1310944
QCR-65
BAY-439006
DTXCID5021128
SCHEMBL29349634
BDBM16673
Nexavar|||BAY 43-9006
4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N-METHYLPICOLINAMIDE
L01XE05
SYN1082
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
VINYLDI-N-OCTYLMETHYLSILANE
BCPP000064
GLXC-90094
HMS2043A18
HMS3244A15
HMS3244A16
HMS3244B15
HMS3656N20
HMS5085J14
BAY 439006
BAY43-9006
K00597a
ACT06732
AOB87782
BCP01767
BCP34023
EX-A2894
Sorafenib, 98% - 10MG 10mg
ZINC1493878
AN-613
BAY439006
CID216239
CS0056
EBC-00643
HY-10201R
NP3268
NSC747971
NSC800934
RS0103
s7397
STK627350
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
BAY-545-9085
Sorafenib for peak identification CRS
AKOS005560229
C21-H16-Cl-F3-N4-O3
AC-1674
ACN-032355
BAY 673472
BAY5459085
CCG-269400
CS-1590
CS-O-11744
DB00398
FS10807
ND-0224
NSC-724772
NSC-747971
NSC-800934
PB14443
SB19942
SDCCGSBI-0634413.P005
SF-0529
BAY 43 9006
BAY 5459085
BAY-43-0006
BAY-54-9085
KS-0000009E
NCGC00167488-01
NCGC00167488-02
NCGC00167488-03
NCGC00167488-04
NCGC00167488-05
NCGC00167488-07
NCGC00167488-11
NCGC00167488-14
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
AK163019
BAY 545 9085
BAY 545-9085
BC679588
BP-44051
BS164413
DA-52659
EN002709
HY-10201
SC-19355
Sorafenib free base (BAY-43-9006)?
SY009239
EC 608-209-4
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
100012-18-8
AB0019677
AB1004622
LS-186067
LS-187021
LS-187788
PA-216239
2161B
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
A3009
A8245
AM20090614
FT-0650736
FT-0674632
NS00005946
SW202562-4
V0124
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
BA4 43 9006
J1.961.269D
C-8800
D08524
EN300-120647
J10391
15216-EP2272827A1
15216-EP2298778A1
15216-EP2311840A1
15216-EP2316832A1
15216-EP2316833A1
AB00933189-05
AB00933189-06
AB00933189_08
461S730
A819449
Q421136
SR-00000000529
1130115-44-4
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
I06-0856
SR-00000000529-1
BRD-K23984367-001-01-8
BRD-K23984367-001-07-5
BRD-K23984367-075-15-2
Z89277543
2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-
475207-59-1
BAY 439006; BAY439006; BAY-439006
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N(SUP 2)-METHYLPYRIDINE-2-CARBOXAMIDE
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
BAX
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
Sorafenib (D3); CM-4307; CM 4307; CM4307;Bay 43-9006 (D3)
1-[4-Chloro-3-(trifluoromethyl)phenyl]-3-[4-[2-(methylcarbamoyl)-4-pyridyloxy]phenyl]urea
4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido) phenoxy)-N-methylpicolinamide
4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido)phenoxy)-N-methylpicolinamide
4-[4-[3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido]phenoxy]-N-methylpyridine-2-carboxamide
N-(3-trifluoromethyl-4-chlorophenyl)-N'-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea
N-Methyl-4-(4-(3-(3-(trifluoromethyl)-4-chlorophenyl)ureido)phenoxy)pyridine-2-carboxamide
1-[4-Chloro-3-(trifluoromethyl)phenyl]-3-[4-[[2-(methylcarbamoyl)-4-pyridyl]oxy]phenyl]urea
1210608-86-8
2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-
2-pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-n-methyl-;sorafenib;4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-n-methyl-2-pyridinecarboxamide;2-pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-n-methyl- sorafenib 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-n-methyl-2-pyridinecarboxamide
2-Pyridinecarboxamide,4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-
4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)phenoxy)-N-methylpyridine-2-carboxamide
4-(4-((4-chloro-3-(trifluoromethyl)phenyl)carbamoylamino)phenoxy)-N-methylpyridine-2-carboxamide
4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)- N-methylpyridine-2-carboxamide
4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide
4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; BAY 43-9006; N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; Nevaxar; Sorafenib
4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-(trideuterio(113C)methyl)pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-picolinamide;tosylic acid
4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-N-methylpyridine-2-carboxamide
4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methyl-pyridine-2-carboxamide
475213-01-5
608-209-4
Manganese(4+), chloro[[4,4',4'',4'''-(21H,23H-porphine-5,10,15,20-tetrayl-kappaN21,kappaN22,kappaN23,kappaN24)tetrakis[1-methylpyridiniumato]](2-)]-, chloride (1:4), (SP-5-12)-
Manganese(4+), chloro[[4,4',4'',4'''-(21H,23H-porphine-5,10,15,20-tetrayl-N21,N22,N23,N24)tetrakis[1-methylpyridiniumato]](2-)]-, chloride (1:4), (SP-5-12)-
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide